Printable Schedule-at-a-Glance (Last updated: 10/20/16)
WEDNESDAY, NOV. 2, 2016
Welcome Reception (Provided)
Group Dinner (Provided)
THURSDAY, NOV. 3, 2016 — Up to 6.5 continuing education credits available — ACPE UAN 0860-0000-16-005-L01-P/0860-0000-16-005-L01-T
Registration and Continental Breakfast
Welcome and Opening Remarks
Keynote Address — Lifestyle Is the Medicine: What's the Spoon? David L. Katz, MD, MPH, FACPM, FACP, Founding Director, Yale University's Yale-Griffin Prevention Research Center; President, American College of Lifestyle Medicine
This talk will first examine what the impact of diet and lifestyle COULD BE on the human condition if knowledge were power. It will then consider the toll associated with our failure to use what we know. The talk will then look closely at the body of evidence relating dietary patterns to human health — and make the case that we are NOT clueless about the basic care and feeding of our species. Endless debate about the details of optimal diets, and an insatiable pop culture fascination with scapegoats and silver bullets — distract us from the well-known fundamentals of healthful eating, and forestall the stunning advances in public health that would ensue were we to turn what we know into what we do. The case will be made that lifestyle is the best, most readily available medicine; and culture could be the spoon that helps it go down.
Telemedicine: Is This the Next Real Innovation in Health Care Delivery?
Telemedicine has continued to grow as a unique way of delivering care to patients, while greatly improving access, reducing cost and positively impacting quality. Despite this staggering increase in users, there are still some barriers preventing its widespread use including technological, financial, and legal obstacles. Dr. Tuckson will discuss current challenges of integrating telemedicine into health care systems and the potential impact of telemedicine on improving health care quality, access, equity, and affordability.
Ethics: First Human Trials and Genetic Screening Coverage, Jeffrey P. Kahn, PhD, MPH, Andreas C. Dracopoulos Director, Johns Hopkins Berman Institute of Bioethics
Mitochondrial pathogenic DNA mutations are responsible for pathological mutations in one out of 5,550 live births, and there are few effective treatment options for people living with these genetic diseases. Consequently, scientists have been developing interventions such as mitochondrial replacement technologies (MRT) whereby mitochondrial DNA (mtDNA) from a healthy donor is used to replace mutated host mtDNA in order to create an embryo that would result in an offspring who would not suffer from mtDNA diseases. Genomic medicine such as this has the capacity to revolutionize clinical practice. However, these rapidly emerging technologies are ethically fraught and lead to concerns about risks and uncertainty for potential offspring created through these techniques, for the donors and prospective parents involved, and for society. In addition, regulators must identify steps for review and approval of such novel reproductive technologies, and payers must determine appropriate approaches for reimbursement decisions — all complicated by limited data on which to make assessments.
During this presentation, Dr. Kahn will describe the issues associated with these new technologies and explore the ethical and policy concerns associated with these rapidly developing biotechnological interventions.
Lunch and Exhibits (Lunch provided)
Providing High Quality Health Care Experiences for Individuals With Intellectual and Developmental Disabilities (IDD), Lynne Tomasa, MSW, PhD, Assistant Professor, Family and Community Medicine, University of Arizona College of Medicine
The Fight Against the Prescription Opioid Abuse Epidemic, Mark D. Sullivan, MD, PhD, UW Medicine
According to the Centers for Disease Control, between 2000 and 2014, the drug epidemic in the United States claimed the lives of half a million people, with 2014 being the most lethal year on record. Of the 28,000 deaths caused by drug overdose in 2014, more than 60 percent were due to an opioid overdose. The goal of this presentation is to explain how health care providers can identify the signs of drug toxicity and understand the risks of opioid use and abuse in their patient population, in addition to learning how to create pain-management plans that do not require opioids for their chronic-pain patients. It will also explain important steps taken by governments and administrations in addressing the prescription opioid abuse epidemic.
Correct Diagnosis and Optimal Management of Migraines, Robert G. Kaniecki, MD, Director, Headache Center; Chief, Headache Division; Assistant Director, Neurology Residency Training Program; Director, Headache Fellowship Program; Assistant Professor, Neurology; Department of Neurology at University of Pittsburgh School of Medicine
Migraine is a common disabling primary headache disorder that affects an estimated 36 million Americans. The correct diagnosis of a headache is necessary in order to begin an effective treatment plan — in one recent study, 72 percent of primary care providers were either not aware or minimally aware of national guidelines for the management of migraine headaches The primary goals of migraine treatment include relieving pain, restoring function, and reducing headache frequency; an additional goal may be preventing progression to chronic migraine. Dr. Kaniecki will discuss the importance of a correct diagnosis, multidisciplinary strategies for the management and prevention of chronic migraine, and the various factors influencing migraine.
Chronic Back Pain Management: What’s New in Treatment Options for this Population? Franz J. Macedo, DO, Medical Director, Comprehensive Pain Center, Minneapolis Veterans Affairs Health Care System; Program Director, Pain Medicine Fellowship, University of Minnesota
It is estimated that 80 percent of Americans will experience some type of back pain within their lifetime. Although guidelines exist for managing back pain, studies suggest that health care providers are not implementing the guidelines. Patients may be treated for acute back pain that will resolve quickly with no residual loss of function. On the other hand, 20 percent of these patients will have chronic back pain that will last greater than 12 weeks. Chronic back pain may be due to a diagnosable anatomical cause or from no clearly identifiable explanation. The treatment for chronic back pain may include a variety of interventions, such as medications, narcotics, nerve-block injections, physical therapy or surgery. During this session, Dr. Macedo will discuss new advancements and solutions for successful management of chronic back pain.
Reception and Exhibits (Reception provided)
Note: OptumHealth Education reserves the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.
Last Updated: 10/20/2016